New stroke drug could boost recovery when given hours after symptoms
NCT ID NCT07389460
First seen Feb 05, 2026 · Last updated Jun 22, 2026 · Updated 18 times
Summary
This phase 3 trial tests whether giving a clot-busting drug called rhPro-UK before a mechanical clot removal procedure improves recovery for people with severe stroke. About 820 participants who had a stroke 4.5 to 24 hours earlier will receive either the drug or a placebo, followed by the standard clot removal. The main goal is to see if more people can live independently 90 days later.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Henan Provincial People's Hospital
Zhengzhou, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Loudi Central Hospital
Loudi, Hunan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Qinghai Provincial People's Hospital
Xining, Qinghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanxi Cardiovascular Hospital
Taiyuan, Shanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Shihezi University
Shihezi, Xinjiang Uygur Autonomous Region, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Hospital of Lanzhou University
Lanzhou, Gansu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Second Hospital of Dalian Medical University
Dalian, Liaoning, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Third Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xuanwu Hospital Capital Medical University
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
recombinant human prourokinase (rhPro-UK)
What this could lead to
If it works, this could offer a new treatment to improve recovery for stroke patients who can't get clot-busting drugs right away.
What could go wrong
This is still being tested, so it may not work better than placebo. There is also a risk of bleeding in the brain, which could be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.